Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning. My name is Mike Connor, and on behalf of the JPMorgan Health Care Investment Banking team, it's our pleasure to introduce Adverum Biotechnologies. As many of you know, Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a onetime individual injection for the treatment of patients with wet AMD and DME.
Today from the company, we are joined by Laurent Fischer, Chief Executive Officer; Leone Patterson, President; and Aaron Osborne, Chief Medical Officer.
I'll now turn it over to Laurent and the team to walk through the presentation. Laurent?
Thank you, Mike. Good morning, everybody. I'd like to first thank JPMorgan for inviting Adverum to present today. And I hope that everybody is doing well and staying safe at home. These are my forward-looking statements on Slide 2. They are also available in our SEC filing and on the Adverum
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |